Benchmark Reiterates Speculative Buy on Unicycive Therapeutics, Maintains $3 Price Target

Benzinga · 05/31/2024 15:09
Benchmark analyst Bruce Jackson reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative Buy and maintains $3 price target.